• Congenital afibrinogenemia causes a potentially lifethreatening bleeding and clotting tendency.
Essentials
• Congenital afibrinogenemia causes a potentially lifethreatening bleeding and clotting tendency.
• Two human fibrinogen concentrates (HFCs) were compared in a randomized pharmacokinetic study.
• Bioequivalence was not shown for AUC norm , which was significantly larger for the new HFC.
• Increases in clot strength were comparable, and no thromboses or deaths occurred in the study.
Summary. Background: Human fibrinogen concentrate (HFC) corrects fibrinogen deficiency in congenital a-/ hypofibrinogenemia. Objectives: To assess pharmacokinetics (PK), effects on thromboelastometry maximum clot firmness (MCF), and safety of a new double virusinactivated/eliminated, highly purified HFC vs. active control. Patients/Methods: In this multinational, randomized, phase II, open-label, crossover study in 22 congenital afibrinogenemia patients aged ≥ 12 years, 70 mg kg À1 of new HFC (FIBRYGA, Octapharma AG) or control (Haemocomplettan Ò P/RiaSTAP TM , CSL Behring GmbH) were administered, followed by crossover to the other concentrate. Fibrinogen activity, PK and MCF in plasma were assessed. Results: The concentrates were not bioequivalent for the primary endpoint, AUC norm (mean ratio, 1.196 
Introduction
Fibrinogen, also known as coagulation factor I, plays a central role in hemostasis, promoting clot formation and platelet aggregation [1] . Following bleeding and activation of the coagulation cascade the substrate fibrinogen is cleaved by thrombin, yielding fibrin monomers that polymerize and subsequently are cross-linked to form a stable, insoluble lattice with platelets, and red and white blood cells, thus impeding blood loss. In addition, fibrin itself has a significant thrombin binding potential, for which reason it was named antithrombin I [1] . Fibrinogen is the most abundant clotting factor in the human circulation, with normal concentrations usually ranging from 1.5 to 4.5 g L À1 [2] , and has a half-life of approximately 4 days [3] . Inherited defects of fibrinogen can affect either the quantity (hypofibrinogenemia and afibrinogenemia) or the quality (dysfibrinogenemia) of circulating fibrinogen. Afibrinogenemia (i.e. lack of detectable fibrinogen in the plasma) is the rarest and most severe form and has an estimated incidence of approximately 1:1 000 000 [4] . It is often diagnosed in the neonatal period, with 85% of cases presenting with umbilical cord bleeds [5] . Patients with afibrinogenemia have a highly variable bleeding tendency that can be severe, including life-threatening bleeding and spontaneous/trauma-related bleeds [3] .
When supplementing fibrinogen levels in patients with a/hypofibrinogenemia to treat or prevent bleeding, the therapeutic goal is to achieve a plasma level of 1 to 1.5 g L
À1
, depending on the severity of the bleeding challenge [6] . In a survey based on data from 100 patients with inherited a/hypofibrinogenemia, the fibrinogen level most frequently recommended for on-demand treatment of minor bleeding was 1 g L À1 , whereas the target for major bleeding (e.g. CNS-related) was 1.5 g L À1 [6] .
Human fibrinogen concentrate (HFC) is the treatment of choice for fibrinogen replacement in patients with congenital fibrinogen deficiency [7] [8] [9] . Cryoprecipitate is used for supplementation of fibrinogen in some countries; however, despite some progress in the use of solvent-detergent methods to treat cryoprecipitate mini-pools [10, 11] , this preparation does not routinely undergo pathogen inactivation [7, 9] . Fibrinogen concentrate is considered to offer benefits over cryoprecipitate in terms of higher purity, more accurate/standardized dosing, faster speed of preparation and administration, no need for blood group matching, decreased allergic reactions and improved safety [7, 9] .
Currently, there is one main plasma-derived HFC indicated for use in congenital fibrinogen deficiency and that is widely available in a number of countries worldwide [12, 13] . A single virus inactivation step (pasteurization) is used in the manufacture of this product [14] [15] [16] .
A new HFC has been developed that undergoes two virus inactivation/elimination steps: solvent/detergent (S/ D) treatment and nanofiltration. It is a freeze-dried, plasma-derived concentrate of human fibrinogen. The manufacturing process of this new product yields a highly-purified fibrinogen concentrate with no stabilizers added. This new HFC is currently undergoing evaluation in a broad clinical development program, which includes establishing the pharmacokinetics, efficacy and safety for on-demand treatment and surgical prophylaxis in adult and pediatric patients with congenital fibrinogen deficiency [17, 18] .
Here , CSL Behring GmbH, Marburg, Germany) in both study periods. Crossover was performed at the end of the first study period (Fig. 1) . Randomization took place before first study drug administration and was performed using a computer-generated randomization schedule to assign the patients, in a blinded manner and in the order of their presentation across all centers, to treatment sequences. One central list balanced over all patients was generated. The study was open-label after randomization. The new HFC and active control were supplied in vials containing 1 g of lyophilized fibrinogen concentrate powder for reconstitution with 50 mL of water for injection. Study medication was administered as an intravenous infusion of 70 mg kg À1 bodyweight À1 according to the label potency of the products.
Inclusion criteria and assessment schedule
The primary inclusion criteria were: age ≥ 12 years; documented congenital afibrinogenemia (i.e. plasma fibrinogen activity and antigen at screening below the detection limit
) from the central laboratory; and informed consent signed by the patient or his or her legal guardian. The primary exclusion criteria were: bleeding disorder other than congenital fibrinogen deficiency; dysfibrinogenemia; treatment with any fibrinogen concentrate or other fibrinogen-containing blood product in the 2 weeks prior to enrolment and/or subsequent study treatment; presence or history of thrombosis; acute bleeding; end-stage liver disease (i.e. Child-Pugh score B or C); planned major surgery with a need for blood transfusion during the pharmacokinetic blood-sampling period of this study; pregnancy or the intention to become pregnant during the study; and polytrauma 1 year prior to enrolment. Blood samples were collected at baseline, at 0.5, 1, 2, 4 and 8 h, and on Days 2, 3, 5, 7, 10 and 14 after infusion of medication, and all samples were tested in a central laboratory. The central laboratory for fibrinogen measurements in plasma, thrombogenicity and MCF was at Lund University, Malm€ o University Hospital, Malm€ o, Sweden, and was blinded from treatment allocation, and the laboratory for virus safety testing was INTERLAB central services-worldwide GmbH in Munich, Germany. Octapharma's quality control laboratory (Vienna, Austria) performed activity testing on the fibrinogen concentrates.
Objectives
The primary objectives were to determine the single-dose pharmacokinetic profile of the new HFC compared with the active control, and to determine MCF as a surrogate marker for hemostatic efficacy before and after administration of either product in patients with congenital afibrinogenemia. The secondary objective was to assess the safety of the new HFC in this population.
Pharmacokinetics
Fibrinogen activity was measured using a modified Clauss assay validated in the central laboratory with a limit of quantification of 0.2 g L À1 .
The following pharmacokinetic parameters were assessed: area under the concentration-time curve (AUC), AUC normalized to the dose administered according to the measured actual potency (AUC norm ), in vivo half-life (t 1/2 ), incremental in vivo recovery (IVR), classical IVR, maximum plasma concentration (C max ), C max normalized to the dose administered according to the measured actual potency (C maxnorm ), time to reach maximum plasma concentration (T max ), mean residence time (MRT), volume of distribution at steady state (V SS ) and clearance (CL). Incremental and classical IVRs were calculated as the maximum increase in plasma fibrinogen activity within 4 hours following infusion when compared with pre-infusion plasma fibrinogen levels.
Efficacy: clot quality (maximum clot firmness)
, Tem International GmbH, Munich, Germany) was used to measure MCF. MCF is a functional parameter that depends on the activation of coagulation and the polymerization and crosslinking of the fibrin network, and is usually measured in whole blood. When measured in plasma, MCF primarily depends on the fibrinogen content of the sample and the resulting fibrin network. MCF in plasma was used as a surrogate marker of hemostatic efficacy [8, 19] at 1 h after administration of either product.
All MCF measurements used frozen citrated plasma samples and the exTEM activator, and were performed in the central laboratory to minimize center-to-center variability. This methodology was used in a previous study of fibrinogen concentrate [8] . 
Safety
Thrombogenicity measurements included prothrombin fragments 1 and 2 (F1 + F2) and D-dimer performed prior to infusion and at 0.5, 1, 2, 4 and 8 h post-infusion on Day 1 of both study periods. Virus safety assessments included testing for HIV-1 and HIV-2, hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV) and parvovirus B19 (parvo B19) by serology and polymerase chain reaction (PCR) assessments. Early allergic reactions and hypersensitivity were monitored and recorded at all post-infusion visits for the first 2 days following any treatment with study medication. Clinical safety was assessed by monitoring vital signs (systolic and diastolic blood pressure, pulse rate, respiratory rate and body temperature) at predefined timepoints, and by monitoring laboratory parameters and adverse events (AEs) throughout the study. Hematological parameters included platelet count, hemoglobin and hematocrit. Clinical chemistry parameters included alanine aminotransferase (ALT), aspartate transaminase (AST), gamma-glutamyl transpeptidase (GGT), alkaline phosphatase, bilirubin total, creatinine and urea, and serum electrolytes (sodium, potassium, bicarbonate and calcium).
Adverse events (AEs) and serious adverse events (SAEs) were reported from Day 1 to Day 45 in each period.
Statistical methods
Because of the limited number of patients for this ultrarare indication, no formal sample size estimations were performed. Instead, the sample size chosen on the basis of study feasibility was shown to have sufficient power for testing bioequivalence regarding AUC within a power calculation that was performed prospectively, in advance of the study start. Bioequivalence was defined as the ratio of AUCs between treatments within the bound of 0.80 to 1.25, equivalent to a mean difference on the log scale within the bound of À0.223 to +0.223. The within-subject standard deviation for AUC (on the log scale) was estimated to be 0.26. With a potential sample size of 18 evaluable patients, and assuming a 5% significance level, the study was estimated to have > 90% power, assuming a true ratio of 1 for the AUC between groups (equivalent to a mean difference of 0 on the log scale). If the true ratio was to be either 0.95 or 1.053 (equivalent to a mean difference of 0.051 on the log scale), the power would still have been over 80%.
Pharmacokinetic analyses were primarily performed in the per-protocol analysis of 21 patients. This excluded one patient who received < 90% of the planned total dose of study medication. For comparison of the pharmacokinetic parameters, 90% confidence intervals (CIs) were calculated for the mean ratio of the new HFC over active control for selected dose-independent or dose-adjusted pharmacokinetic parameters. Based on log-transformed AUC norm , bioequivalence of the two products was assessed using a 2 9 2 crossover analysis of variance model (assuming independence and a normal distribution for the patient effect and error, and treatment effect and period effect as fixed effects) to test whether the 90% CI for the mean ratio of AUC norm was within the range 0.8-1.25, as specified in the statistical calculations prior to the study start. The null hypothesis was non-equivalence (AUC norm ratio < 0.8 or > 1.25). Following the observation of non-equivalence for some pharmacokinetic parameters, tests of the null hypothesis of no difference (ratio=1) were performed post hoc using ANOVA type 3 tests of fixed effects in order to further characterize any differences in the pharmacokinetic parameters between the new HFC and the active control. Descriptive P-values are provided accordingly.
For comparison of hemostatic efficacy, prespecified 95% CIs were calculated for the mean difference in the 1-h MCF plasma values between the two products. Safety variables were analyzed descriptively. MCF and safety were assessed in the full analysis patient dataset (n = 22).
Results

Patient characteristics
Twenty-seven patients were screened, of whom five were screening failures and 22 patients were treated in the study. In accordance with the inclusion criteria, patients were older than 12 years of age, with a median (range) age of 23 (12-53) years. Of the 22 patients, 14 (63.6%) were of White race and eight (36.4%) were Asian; six (27.3%) patients were between 12 and < 18 years old, and 16 (72.7%) were aged ≥ 18 years (Table 1) . 
Pharmacokinetics and maximum clot firmness
The primary analyses were performed on data from 21 patients. At baseline, fibrinogen concentrations were at or below the limit of detection of the assays in all patients, as expected in this patient population. ) and 30 min of the active control (1.222 g L À1 ), and for both groups decreased to pre-infusion levels by 216 h (9 days) (Fig. 2) . Over the first 144 h (6 days), the mean plasma fibrinogen concentrations measured for the new HFC showed higher values than those observed with the active control (Fig. 2) . In the per-protocol analysis (n = 21), the mean ratio of the new HFC to active control for AUC norm was 1.196 (90% CI, 1.117, 1.281) ( Table 2 ). Analysis of the mean ratio for AUC norm in all patients (n = 22) showed comparable results to the primary analysis (1.217; 90% CI, 1.133, 1.307). Consequently, bioequivalence was not demonstrated for the primary endpoint of the study. Bioequivalence was also not demonstrated for clearance, with mean ratio of 0.836 (90% CI, 0.781, 0.895). Furthermore, for V ss , a mean ratio of 0.886 (90% CI 0.791, 0.994) was observed. For the remaining pharmacokinetic parameters, the 90% CI for the mean ratios were within the range 0.8-1.25, reflecting bioequivalence between the two products ( Table 2) .
Values for pharmacokinetic parameters with each study medication are shown in Table 3 (corresponding data for all patients [n = 22] are provided in Table S1 ). In the post-hoc analyses, the mean AUC norm calculated for fibrinogen activity was significantly larger for the new HFC than for the active control (1.62 AE 0.45 vs. 1.38 AE 0.47 h kg g L À1 mg
À1
, P = 0.0002). For the two remaining pharmacokinetic parameters that did not demonstrate bioequivalence, clearance and V ss , ANOVA only showed significant differences between products in the mean value for clearance, which was significantly slower for the new HFC compared with the active control (0.665 AE 0.197 vs. 0.804 AE 0.255 mL h À1 kg À1 , P = 0.0002). These data indicate that the new HFC was at least as efficacious as the active control for increasing fibrinogen activity. Furthermore, although the numbers are small, mean values for AUC norm and clearance for the new HFC were similar in patients < 18 (n = 5) and ≥ 18 years old (n = 16) (AUC norm , 1.573 and 1.640 h kg g L À1 mg À1 , respectively; clearance, 0.675 and 0.661 mL h À1 kg À1 , respectively).
As expected, a significant increase in mean plasma MCF from baseline (all 0.00 mm) to 1 h after administration was observed with the new HFC (9.68 mm) and with active control (10.00 mm) (both P < 0.0001; Table 4 ). The mean difference between the 1-hour post-infusion MCF values was À0.32 mm (95% CI, À1.70, 1.07); the confidence interval included zero, indicating that the difference between treatments was not significant (Fig. 3) .
Safety
Adverse events generally occurred as single events in individual patients. The incidence and nature of AEs after administration of the new HFC and active control are shown for all 22 patients in Table 5 .
Two AEs occurring in two patients were considered to be possibly related to the new HFC: one mild pyrexia and one mild allergic skin reaction. One severe AE AUC, area under the concentration-time curve; AUC norm , area under the concentration-time curve normalized to the dose administered; C max , maximum plasma concentration; C maxnorm , maximum plasma concentration normalized to the dose administered; CL, clearance; HFC, human fibrinogen concentrate; IVR, in vivo recovery; MRT, mean residence time; SD, standard deviation; t 1/2 , halflife; T max , time to reach maximum plasma concentration; V ss , volume of distribution at steady state. *Per protocol patient analysis set. (urinary tract infection) occurred 6 days after infusion of the new HFC but was not considered to be related to treatment. One patient experienced two SAEs on the same day (abdominal pain and vaginal hemorrhage), 25 days after receiving the new HFC; these events were also not considered to be treatment related.
No deaths occurred following administration of either study medication and no severe allergic reactions, cases of thromboembolism or clinically relevant changes in prothrombin F1 + F2 and D-dimer relative to pre-infusion levels were observed. No clinically abnormal vital signs were observed during the study, and there were no seroconversions for HIV, HAV, HBV, HCV or parvovirus B19 after infusion of either product. No clinically significant abnormalities in clinical chemistry parameters were recorded with either HFC.
Discussion
This phase II, randomized trial in congenital afibrinogenemia patients represents the first phase of the clinical development of a new fibrinogen concentrate, and compared single-dose pharmacokinetics, efficacy and safety of this newly developed fibrinogen concentrate vs. a commercially available fibrinogen concentrate. The study found broadly comparable pharmacokinetic profiles of the two fibrinogen concentrates, except that the bioequivalence criteria for the primary endpoint AUC norm and for the pharmacokinetic parameters clearance and V ss were not reached, and demonstrated a statistically significant increase in fibrin clot quality after infusion, which translates into a potential to promote hemostasis in bleeding situations. The post-hoc ANOVA analyses on the pharmacokinetic parameters that did not reflect bioequivalence showed significant differences between the treatments for the area under the concentration-time curve, which was significantly larger, and for clearance, which was significantly slower, with the new HFC vs. the active control. Maximum clot firmness was significantly increased at 1 h post-infusion with both products, demonstrating similar efficacy in restoring clot strength. Both products showed a favorable safety profile with no deaths, thrombotic events, severe allergic reactions or viral seroconversions related to either treatment.
Plasma fibrinogen concentration peaked within 2 h after administration with both products, and levels achieved were well within the recommended target (1-1.5 g L À1 ) [6] and very similar to those observed in a previous study performed with the active control (median of 1.3 g L
À1
) [8] . The observations that bioequivalence criteria were not reached for AUC norm and that the new HFC showed a significantly larger AUC norm vs. the active control were surprising. Although the corresponding C maxnorm values were similar between the two concentrates, some differences were observed in their respective pharmacokinetic profiles. Plasma fibrinogen concentration peaked earlier after administration of active control (median T max 0.5 h), whereas the peak after HFC was flatter, with a median T max of 2.0 h. Following this initial phase, elimination of the two concentrates was almost parallel; t 1/2 was slightly longer with HFC vs. active control, but within the range of bioequivalence. Thus, the initial difference in the pharmacokinetic profiles could be the main determinant of the higher AUC norm with HFC when compared with the active control. Another potential cause of this difference may be the slower clearance observed, which could imply enhanced persistence of the new HFC in the circulation due to increased product purity, although the mechanism for this requires further study.
As for the comparison with data published so far, most pharmacokinetic measurements were broadly in line with values reported in previous studies of fibrinogen concentrates [8, 20] . Slight differences in individual parameters, for instance median t 1/2 of 77.1 h for the active control reported by a previous study [8] , compared with 64.6 h observed in the current study, might be due to the variability brought about by the small sample sizes used in both studies. Nevertheless, given the robustness of the crossover design of the current study, these results should provide an accurate indication of the differences between the two products.
MCF has been established in in vitro and clinical studies of patients with congenital fibrinogen deficiency as a good marker for the global quality and integrity of the clotting process following administration of fibrinogen concentrate [8, 19] . The rapid increases in MCF we observed after a single infusion of medication were consistent with that seen in a previous study [8] . The observed changes in MCF values also closely matched the levels expected from in vitro spiking experiments performed using plasma samples from individuals with fibrinogen deficiency and known amounts of exogenous fibrinogen [19] . The increase in MCF using exTEM activator in citrated plasma samples is very encouraging, but it must be kept in mind that results obtained using plasma are not equivalent to results obtained using whole blood, which is more commonly used in clinical practice, in particular in the settings of perioperative bleeding and trauma. It cannot be estimated what impact fibrinogen supplementation would have had on whole blood ROTEM analyses. Whole blood ROTEM analyses are challenging for multicenter studies in congenital afibrinogenemia; the rarity of the disease and its variability in geographic distribution, together with the need for user training and quality control, make centralized testing of plasma samples more applicable for the congenital fibrinogen deficiency setting. Regarding safety, we observed favorable profiles for both the new HFC and the active control, the latter being an established human fibrinogen concentrate product with extensive pharmacovigilance data collected since it first became commercially available 30 years ago [21] . Adverse events generally occurred as single events in individual patients. There were no deaths, thrombotic events or severe allergic reactions in the study, nor were there seroconversions related to either treatment. These findings are in line with data reported previously, which indicate a low rate of adverse events following use of fibrinogen concentrate in populations including patients with inherited deficiency [8, 21] .
Our study has some limitations. With 22 patients included in the analysis, the patient cohort may be considered small, although the randomized crossover design is a rigorous test of the comparison and the study was well powered to test bioequivalence. Given that afibrinogenemia is a very rare bleeding disorder, our study population was relatively large compared with previous studies conducted in this setting [8, 15, 20] . There were limitations regarding the efficacy and safety analyses: the assessment of hemostatic efficacy was carried out through the surrogate measure of MCF, and the study was not powered to formally compare the safety of the two fibrinogen concentrates.
Further studies will need to incorporate direct measures of clinical efficacy. For example, the primary outcome measure of the ongoing phase III FORMA-02 study (NCT02267226) is clinical assessment of the hemostatic efficacy of the new HFC in treating acute bleeding episodes (spontaneous or after trauma) in patients aged ≥ 12 years with congenital afibrinogenemia or severe hypofibrinogenemia [17] . These data, together with data from the ongoing phase III FORMA-04 pediatric study (NCT02408484) [18] , will provide a better understanding of how the pharmacokinetic and plasma MCF findings from the current study translate into the bleeding and perioperative setting, where prompt cessation of bleeding and restoration of hemostasis are required.
In conclusion, this randomized, controlled, single-dose, crossover trial showed that the new HFC did not reach the bioequivalence criteria for the primary endpoint of the study, AUC norm . From the remaining pharmacokinetic parameters, the same was observed for clearance and V ss . ANOVA analyses on these parameters showed a significantly larger AUC norm and slower clearance when compared with another fibrinogen concentrate. The new HFC significantly increased clot strength 1 h after dosing, to a similar degree to the active control. The safety and tolerability profile was favorable. Additional investigations will be required to ascertain the mechanism and potential clinical impact of the favorable pharmacokinetic profile observed with this new concentrate. In the meantime, these results suggest the profile of this product to be effective for raising fibrinogen levels and correcting the clotting ability of the blood, features that are needed in the treatment and prevention of bleeding in adult and pediatric patients with congenital fibrinogen deficiency. Clinical treatment studies with the new fibrinogen concentrate are ongoing. 
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